India’s ‘other’ COVID vaccines: The status of under-trial, approved and unused jabs

News Today 19.05.2022

As India nears the 200-crore COVID-19 vaccination mark, Serum Institute of India’s (SII) Covishield accounts for 80 per cent (154 crore) of the jabs, while Bharat Biotech’s Covaxin accounts for 16.75 per cent (32 crore) jabs. Of the 191 crore jabs administered till now, the remaining three vaccines used — Gamelaya’s Sputnik –V, Biological E’s Corbevax and Novovax-SII’s Covovax — account only for 3.25 per cent (6.25 crore) altogether. (Read More)


Be the first to comment

Leave a Reply

Your email address will not be published.